Cargando…
Long-Term Effect of Switching From an Anti-CGRP Receptor to an Anti-CGRP Ligand Antibody in Treatment-Refractory Chronic Migraine: A Prospective Real-World Analysis
In migraine patients with a poor response to a calcitonin gene-related peptide monoclonal antibody against the receptor, switching to a calcitonin gene-related peptide monoclonal antibodies against the ligand may be beneficial. This was a long-term real-world prospective analysis conducted in treatm...
Autores principales: | Lambru, Giorgio, Caponnetto, Valeria, Hill, Bethany, Ratti, Susanna, Sacco, Simona, Murphy, Madeleine, Briscoe, Jessica, Andreou, Anna P. |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Springer International Publishing
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10480365/ https://www.ncbi.nlm.nih.gov/pubmed/37430146 http://dx.doi.org/10.1007/s13311-023-01394-0 |
Ejemplares similares
-
CGRP in migraine
por: Tfelt-Hansen, Peer, et al.
Publicado: (2009) -
CGRP and migraine
por: Cauchi, M., et al.
Publicado: (2016) -
Understanding side-effects of anti-CGRP and anti-CGRP receptor antibodies
por: Haanes, Kristian Agmund, et al.
Publicado: (2020) -
New Anti-CGRP Medications in the Treatment of Vestibular Migraine
por: Hoskin, Justin L., et al.
Publicado: (2022) -
Serotonin and CGRP in Migraine
por: Aggarwal, Milan, et al.
Publicado: (2012)